Skip to main content
. 2017 Sep;58(9):1386–1394. doi: 10.2967/jnumed.116.187310

FIGURE 1.

FIGURE 1.

Graphic of MET/HGF system illustrating therapeutic approaches currently used to target it (top), including HGF-binding/neutralizing antibodies, MET-binding antagonists, and MET tyrosine kinase inhibitors, and depiction of antibodies tagged with radioactive metal (89Zr) for use in immuno-PET of HGF/MET+ cancers (bottom).